Literature DB >> 24096617

Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations.

Ian R Mackenzie1, Thomas Arzberger, Elisabeth Kremmer, Dirk Troost, Stefan Lorenzl, Kohji Mori, Shih-Ming Weng, Christian Haass, Hans A Kretzschmar, Dieter Edbauer, Manuela Neumann.   

Abstract

Hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of frontotemporal dementia and motor neuron disease. Recently, unconventional non-ATG translation of the expanded hexanucleotide repeat, resulting in the production and aggregation of dipeptide repeat (DPR) proteins (poly-GA, -GR and GP), was identified as a potential pathomechanism of C9ORF72 mutations. Besides accumulation of DPR proteins, the second neuropathological hallmark lesion in C9ORF72 mutation cases is the accumulation of TDP-43. In this study, we characterized novel monoclonal antibodies against poly-GA and performed a detailed analysis of the neuroanatomical distribution of DPR and TDP-43 pathology in a cohort of 35 cases with the C9ORF72 mutation that included a broad spectrum of clinical phenotypes. We found the pattern of DPR pathology to be highly consistent among cases regardless of the phenotype with high DPR load in the cerebellum, all neocortical regions (frontal, motor cortex and occipital) and hippocampus, moderate pathology in subcortical areas and minimal pathology in lower motor neurons. No correlation between DPR pathology and the degree of neurodegeneration was observed, while a good association between TDP-43 pathology with clinical phenotype and degeneration in key anatomical regions was present. Our data confirm that the presence of DPR pathology is intimately related to C9ORF72 mutations. The observed dissociation between DPR inclusion body load and neurodegeneration might suggest inclusion body formation as a potentially protective response to cope with soluble toxic DPR species. Moreover, our data imply that alterations due to the C9ORF72 mutation resulting in TDP-43 accumulation and dysmetabolism as secondary downstream effects likely play a central role in the neurodegenerative process in C9ORF72 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24096617     DOI: 10.1007/s00401-013-1181-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  143 in total

Review 1.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease.

Authors:  Joseph Amick; Shawn M Ferguson
Journal:  Traffic       Date:  2017-03-23       Impact factor: 6.215

3.  Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Authors:  David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2017-08-19       Impact factor: 10.422

Review 4.  Dementia in 2013: frontotemporal lobar degeneration-building on breakthroughs.

Authors:  Julie van der Zee; Christine Van Broeckhoven
Journal:  Nat Rev Neurol       Date:  2014-01-07       Impact factor: 42.937

Review 5.  Mechanisms of toxicity in C9FTLD/ALS.

Authors:  Tania F Gendron; Veronique V Belzil; Yong-Jie Zhang; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2014-01-07       Impact factor: 17.088

Review 6.  Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.

Authors:  John Douglas Cleary; Laura P W Ranum
Journal:  Curr Opin Genet Dev       Date:  2014-05-22       Impact factor: 5.578

7.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 8.  Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  Zongbing Hao; Rui Wang; Haigang Ren; Guanghui Wang
Journal:  Neurosci Bull       Date:  2020-08-29       Impact factor: 5.203

9.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.

Authors:  Elaine Y Liu; Jenny Russ; Kathryn Wu; Donald Neal; Eunran Suh; Anna G McNally; David J Irwin; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2014-05-08       Impact factor: 17.088

Review 10.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.